Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This placebo-controlled, double-blind, randomized pilot clinical trial will evaluate
atomoxetine (Strattera®) for the treatment of cocaine dependence. Cocaine-dependent
individuals, who are healthy and are seeking treatment for their substance abuse, will be
randomized to receive either atomoxetine (n=25) or a matched-placebo (n=25) during a trial
lasting 12 weeks; there will be a double-blind, ascending dose lead-in order to achieve
maintenance on the assigned active dose safely. Contingency management procedures will be
used to reinforce attendance and compliance with study procedures. Primary outcome measures
will include urinalysis data assessing cocaine use.
Phase:
Phase 2
Details
Lead Sponsor:
Sharon Walsh University of Kentucky
Collaborators:
Eli Lilly and Company National Institute on Drug Abuse (NIDA)